Holen Sie sich die Stockscreener-App
0.5686
2.26%
-0.0166
Schlusskurs vom Vortag:
$0.5851
Offen:
$0.59
24-Stunden-Volumen:
864.10K
Relative Volume:
0.14
Marktkapitalisierung:
$78.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.2247
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+3.05%
1M Leistung:
-14.64%
6M Leistung:
+62.10%
1J Leistung:
-52.34%
1-Tages-Spanne:
$0.5685
$0.5985
1-Wochen-Bereich:
$0.5357
$0.613
52-Wochen-Spanne:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Firmenname
Plus Therapeutics Inc
Sektor
Branche
Telefon
737.255.7194
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Vergleichen Sie PSTV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.5698 | 80.41M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.91 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.66 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.96 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
How Plus Therapeutics Inc. (XMP0) stock expands through international marketsDurability and Wear Notes & support options for steady strides - ulpravda.ru
Why Plus Therapeutics Inc. stock is a value investor pickStop Loss & AI Based Buy/Sell Signal Reports - ulpravda.ru
Is Plus Therapeutics Inc. stock cheap at current valuationWeekly Profit Summary & Weekly Return Optimization Plans - ulpravda.ru
Is Plus Therapeutics Inc. stock a buy in volatile markets2025 Key Lessons & Advanced Swing Trade Entry Plans - ulpravda.ru
Can Plus Therapeutics Inc. stock continue upward trendEarnings Growth Report & Daily Price Action Insights - ulpravda.ru
Plus Therapeutics completes FDA meeting on REYOBIQ trial strategy By Investing.com - Investing.com India
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial By Investing.com - Investing.com South Africa
Plus Therapeutics stock falls after FDA meeting on REYOBIQ trial - Investing.com
Plus Therapeutics Stock (PSTV) Opinions on FDA Meeting for REYOBIQ™ Approval - Quiver Quantitative
PSTV: Today's Analyst Ratings Maintains 'Buy' with Consistent Pr - GuruFocus
Plus Therapeutics (PSTV) Advances with FDA on REYOBIQ Trial for Leptomeningeal Metastases - GuruFocus
Plus Therapeutics announces read out of Type B meeting with the FDA - MarketScreener
Plus Therapeutics, Inc. Completes FDA Type B Meeting on REYOBIQ Pivotal Trial Strategy for Leptomeningeal Metastases - Quiver Quantitative
No approved drugs for this cancer: FDA shapes path for a possible new option - Stock Titan
How Plus Therapeutics Inc. stock reacts to job market dataSector Performance Drivers & Minimal Capital Trading - ulpravda.ru
2026 world cup points table rankings: How Plus Therapeutics Inc. stock responds to policy changes2026 world cup usa national team round of 32 star players set piece tactics knockout prediction tactical review - ulpravda.ru
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analyst Downgrade: How Plus Therapeutics Inc XMP0 stock expands through international marketsMarket Risk Summary & Accurate Intraday Trade Tips - moha.gov.vn
Guidance Update: Can Plus Therapeutics Inc XMP0 stock attract analyst upgradesJuly 2025 Setups & Safe Entry Momentum Tips - moha.gov.vn
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
How Plus Therapeutics Inc. stock responds to policy changes2025 Market Overview & Safe Entry Momentum Tips - ulpravda.ru
Is Plus Therapeutics Inc. (XMP0) stock a top hedge fund pick2025 Momentum Check & Real-Time Stock Price Movement Reports - Улправда
Can Plus Therapeutics Inc. (XMP0) stock ride next bull market cycleQuarterly Trade Summary & Weekly Breakout Stock Alerts - Улправда
Plus Therapeutics, Inc. (PSTV) Presents at 2025 San Antonio Breast Cancer Symposium (SABCS)Slideshow - Seeking Alpha
Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting | PSTV Stock News - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):